XOMA

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)

06/30 06:14 pm

XOMA Royalty Declares Quarterly Preferred Stock Dividends

06/18 07:30 am

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

05/27 08:01 am

XOMA Royalty Declares Quarterly Preferred Stock Dividends

03/20 07:30 am

XOMA Royalty Declares Quarterly Preferred Stock Dividends

12/19 08:30 am

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

12/02 08:30 am

XOMA Corp to rebrand as XOMA Royalty Corporation By Investing.com - Investing.com

07/09 11:12 am

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

06/29 02:31 am

Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?

06/21 07:54 am

XOMA Declares Quarterly Preferred Stock Dividends

06/20 07:30 am

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

06/12 07:30 am

Peeling Back The Layers: Exploring XOMA Through Analyst Insights

05/31 08:00 am

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

05/14 07:30 am

Certara, Inc. (CERT) Q1 Earnings Meet Estimates

05/07 06:40 pm

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates

05/02 06:05 pm

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

04/30 07:30 am

Cracking The Code: Understanding Analyst Reviews For XOMA

04/29 10:00 am

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

04/25 07:30 am

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

03/19 04:05 pm

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

03/08 08:30 am

XOMA to Present at Upcoming Investor Conferences in March

02/28 08:30 am

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

02/16 09:00 am

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

01/18 09:30 am

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

01/11 05:05 pm

XOMA Announces Stock Repurchase Program of up to $50 Million

01/02 08:30 am

XOMA Declares Quarterly Preferred Stock Dividends

12/20 08:30 am

I'm Buying Preferred Stocks Hand Over Fist

12/15 09:30 am

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

11/07 08:30 am

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

10/31 07:30 am

Ride The Royalty Ripple To Riches Like Charlie Munger

10/06 07:35 am

XOMA Declares Quarterly Preferred Stock Dividends

09/25 07:30 am

Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?

09/18 12:41 pm

XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

09/06 07:30 am

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

08/08 07:30 am

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

08/02 06:15 pm

XOMA Added to the Russell 2000® and Russell 3000® Indexes

06/23 06:14 pm

Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst

06/22 03:09 pm

XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset

06/22 07:30 am

XOMA Declares Quarterly Preferred Stock Dividends

06/20 07:30 am

XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy

05/09 07:30 am

Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?

04/28 03:28 am

XOMA to Present at H.C. Wainwright BioConnect Investor Conference

04/26 07:30 am

XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio

03/30 07:30 am

XOMA Declares Quarterly Preferred Stock Dividends

03/21 07:30 am

XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy

03/09 08:30 am

XOMA to Present at 43rd Annual Cowen Health Care Conference

02/28 08:30 am

XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/06 08:00 pm

New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy

01/04 08:30 am

XOMA Declares Quarterly Preferred Stock Dividends

12/22 08:30 am

XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon

11/22 08:01 am